J9275 Cosibelimab-ipdl - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Cosibelimab-ipdl

Brand Name:

UNLOXCYT

Strength:

2mg

HCPCS:

J9275

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Checkpoint Inhibitor

Minor Drug Class:

PD-L1

Oral (Y/N):

No

FDA Approval Year:

2025

FDA Discontinuation Year:

CMS Effective Date:

July 9, 2025

CMS Discontinuation Date:

Status:

In Use